Safety and tolerability of the oral Xa inhibitor darexaban for secondary prevention after acute coronary syndromes
Tuesday, August 30, 2011 - 10:30
in Health & Medicine
A phase II dose-finding study has found that the new oral Factor Xa inhibitor darexaban was associated with a two to four-fold increase in bleeding when added to dual antiplatelet therapy in patients following an acute coronary syndrome.